Analyst B. Riley upgraded Madrigal Pharmaceuticals' rating from sell to neutral, raising the target price from $155 to $270.

B. Riley raised Madrigal Pharmaceuticals' (NASDAQ: MDGL) rating from a sell to a neutral, increasing their target price from $155 to $270. The biopharmaceutical company has also received price target upgrades from other analysts, such as Oppenheimer ($320 to $375), JMP Securities ($351 to $397), and TD Cowen ($349 to $390). These upgrades suggest potential growth for the company and have attracted attention from investors.